Advanced
Cellular Science. Real Human Possibilities.

BrainXell Therapeutics is developing autologous, iPSC-derived cell therapies that enable patients to reclaim their lives by replacing what’s been lost to neurodegenerative diseases.

What Drives Us
Estimated number of people worldwide living with Parkinson's disease (PD) – expected to double by 2050
Over 10 million
Estimated number of people worldwide diagnosed with PD every year
1.2 million
When a patient with PD begins to exhibit motor challenges more than half of the dopamine in their brain has been depleted
Over 60%
Estimated number of deaths annually worldwide due to PD and expected to increase  as our population ages
350,000
At BrainXell we utilize our proprietary technology of directed differentiation to expertly develop iPSC-derived neuronal cells to restore function.
Company
How it worksPricingDocs
Resources
Blog post name list goes hereBlog post name list goes hereBlog post name list goes hereSee all resources >
Terms & ConditionsPrivacy policy
© 2026 BrainXell Therapeutics. All Rights Reserved. Site by The Grace Communication Group.